Topical minoxidil-loaded nanotechnology strategies for alopecia
Main Author: | |
---|---|
Publication Date: | 2020 |
Other Authors: | , , , , , , , |
Format: | Article |
Language: | eng |
Source: | Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
Download full: | https://hdl.handle.net/10216/143566 |
Summary: | Androgenetic alopecia (AGA) is a multifactorial and age-related condition characterized by substantial hair loss affecting both men and women. Conventional treatments include the use of topical minoxidil (MNX) formulations to stimulate hair growth and restore hair condition. However, those treatments are associated with limited performance and a lack of tolerability and compliance due to the emergence of adverse effects. Considering that the development of nanotechnology-based formulations as hair loss therapeutic strategies has been clearly growing, topical MNX delivery by means of these innovative formulations is known to enhance MNX skin permeation and depot formation into hair follicles, allowing for MNX-controlled release, increased MNX skin bioavailability and enhanced therapeutic ecacy with minimal adverse effects. This review highlights the potential of nanotechnology-based MNX delivery formulations for improved hair loss therapeutics, including a thorough assessment of their in vitro and in vivo performances, as well as regulatory and nanosafety considerations. |
id |
RCAP_8923861d45c756f65e778dd9ebfeffbf |
---|---|
oai_identifier_str |
oai:repositorio-aberto.up.pt:10216/143566 |
network_acronym_str |
RCAP |
network_name_str |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
repository_id_str |
https://opendoar.ac.uk/repository/7160 |
spelling |
Topical minoxidil-loaded nanotechnology strategies for alopeciaAlopeciaHairMinoxidilNanoparticleNanotechnologySkinTopical deliveryAndrogenetic alopecia (AGA) is a multifactorial and age-related condition characterized by substantial hair loss affecting both men and women. Conventional treatments include the use of topical minoxidil (MNX) formulations to stimulate hair growth and restore hair condition. However, those treatments are associated with limited performance and a lack of tolerability and compliance due to the emergence of adverse effects. Considering that the development of nanotechnology-based formulations as hair loss therapeutic strategies has been clearly growing, topical MNX delivery by means of these innovative formulations is known to enhance MNX skin permeation and depot formation into hair follicles, allowing for MNX-controlled release, increased MNX skin bioavailability and enhanced therapeutic ecacy with minimal adverse effects. This review highlights the potential of nanotechnology-based MNX delivery formulations for improved hair loss therapeutics, including a thorough assessment of their in vitro and in vivo performances, as well as regulatory and nanosafety considerations.MDPI20202020-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10216/143566eng2079-928410.3390/COSMETICS7020021Santos, ACPereira-Silva, MGuerra, CCosta, DPeixoto, DPereira, IPita, IRibeiro, AVeiga, Finfo:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2025-02-27T17:15:31Zoai:repositorio-aberto.up.pt:10216/143566Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-28T22:08:21.909213Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse |
dc.title.none.fl_str_mv |
Topical minoxidil-loaded nanotechnology strategies for alopecia |
title |
Topical minoxidil-loaded nanotechnology strategies for alopecia |
spellingShingle |
Topical minoxidil-loaded nanotechnology strategies for alopecia Santos, AC Alopecia Hair Minoxidil Nanoparticle Nanotechnology Skin Topical delivery |
title_short |
Topical minoxidil-loaded nanotechnology strategies for alopecia |
title_full |
Topical minoxidil-loaded nanotechnology strategies for alopecia |
title_fullStr |
Topical minoxidil-loaded nanotechnology strategies for alopecia |
title_full_unstemmed |
Topical minoxidil-loaded nanotechnology strategies for alopecia |
title_sort |
Topical minoxidil-loaded nanotechnology strategies for alopecia |
author |
Santos, AC |
author_facet |
Santos, AC Pereira-Silva, M Guerra, C Costa, D Peixoto, D Pereira, I Pita, I Ribeiro, A Veiga, F |
author_role |
author |
author2 |
Pereira-Silva, M Guerra, C Costa, D Peixoto, D Pereira, I Pita, I Ribeiro, A Veiga, F |
author2_role |
author author author author author author author author |
dc.contributor.author.fl_str_mv |
Santos, AC Pereira-Silva, M Guerra, C Costa, D Peixoto, D Pereira, I Pita, I Ribeiro, A Veiga, F |
dc.subject.por.fl_str_mv |
Alopecia Hair Minoxidil Nanoparticle Nanotechnology Skin Topical delivery |
topic |
Alopecia Hair Minoxidil Nanoparticle Nanotechnology Skin Topical delivery |
description |
Androgenetic alopecia (AGA) is a multifactorial and age-related condition characterized by substantial hair loss affecting both men and women. Conventional treatments include the use of topical minoxidil (MNX) formulations to stimulate hair growth and restore hair condition. However, those treatments are associated with limited performance and a lack of tolerability and compliance due to the emergence of adverse effects. Considering that the development of nanotechnology-based formulations as hair loss therapeutic strategies has been clearly growing, topical MNX delivery by means of these innovative formulations is known to enhance MNX skin permeation and depot formation into hair follicles, allowing for MNX-controlled release, increased MNX skin bioavailability and enhanced therapeutic ecacy with minimal adverse effects. This review highlights the potential of nanotechnology-based MNX delivery formulations for improved hair loss therapeutics, including a thorough assessment of their in vitro and in vivo performances, as well as regulatory and nanosafety considerations. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020 2020-01-01T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://hdl.handle.net/10216/143566 |
url |
https://hdl.handle.net/10216/143566 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
2079-9284 10.3390/COSMETICS7020021 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
MDPI |
publisher.none.fl_str_mv |
MDPI |
dc.source.none.fl_str_mv |
reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia instacron:RCAAP |
instname_str |
FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
collection |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
repository.name.fl_str_mv |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia |
repository.mail.fl_str_mv |
info@rcaap.pt |
_version_ |
1833599568326950912 |